SG Americas Securities LLC Has $20.96 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

SG Americas Securities LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4,857.2% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 567,653 shares of the biotechnology company's stock after buying an additional 556,202 shares during the period. SG Americas Securities LLC owned approximately 0.20% of Exelixis worth $20,958,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in EXEL. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its holdings in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares in the last quarter. Principal Securities Inc. grew its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 373 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insiders Place Their Bets

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the sale, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 100,000 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $46.00, for a total value of $4,600,000.00. Following the completion of the sale, the chief financial officer now owns 967,842 shares of the company's stock, valued at $44,520,732. This represents a 9.36% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 458,113 shares of company stock valued at $21,024,817. 2.82% of the stock is currently owned by insiders.

Exelixis Stock Performance

NASDAQ:EXEL traded up $0.35 on Thursday, hitting $41.78. 2,192,721 shares of the stock were exchanged, compared to its average volume of 2,351,247. The stock has a market capitalization of $11.39 billion, a price-to-earnings ratio of 23.60, a P/E/G ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 52 week low of $21.36 and a 52 week high of $48.85. The company's 50-day moving average price is $39.54 and its 200 day moving average price is $36.83.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. HC Wainwright raised their target price on Exelixis from $40.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday. Citigroup raised their target price on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. UBS Group restated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, Piper Sandler raised their target price on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Exelixis currently has an average rating of "Moderate Buy" and an average target price of $39.76.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.